Nimacimab
Obesity (combination therapy)
Key Facts
About Skye Bioscience
Skye Bioscience is pioneering a novel approach to metabolic disease by targeting the peripheral cannabinoid 1 (CB1) receptor, a mechanism previously validated for obesity in Europe but limited by central nervous system side effects. The company's lead asset, nimacimab, is a peripherally-restricted CB1-inhibiting antibody that demonstrated positive Phase 2a combination data with semaglutide, showing additional weight loss without increased gastrointestinal or neuropsychiatric adverse events. Skye is strategically advancing nimacimab through clinical development and exploring partnerships, including a recent collaboration with Halozyme, to position CB1 inhibition as a complementary mechanism in the large and heterogeneous obesity market.
View full company profileAbout Skye Bioscience
Skye Bioscience is pioneering a novel approach to metabolic disease by targeting the peripheral cannabinoid 1 (CB1) receptor, a mechanism previously validated for obesity in Europe but limited by central nervous system side effects. The company's lead asset, nimacimab, is a peripherally-restricted CB1-inhibiting antibody that demonstrated positive Phase 2a combination data with semaglutide, showing additional weight loss without increased gastrointestinal or neuropsychiatric adverse events. Skye is strategically advancing nimacimab through clinical development and exploring partnerships, including a recent collaboration with Halozyme, to position CB1 inhibition as a complementary mechanism in the large and heterogeneous obesity market.
View full company profileAbout Skye Bioscience
Skye Bioscience is pioneering a novel approach to metabolic disease by targeting the peripheral cannabinoid 1 (CB1) receptor, a mechanism previously validated for obesity in Europe but limited by central nervous system side effects. The company's lead asset, nimacimab, is a peripherally-restricted CB1-inhibiting antibody that demonstrated positive Phase 2a combination data with semaglutide, showing additional weight loss without increased gastrointestinal or neuropsychiatric adverse events. Skye is strategically advancing nimacimab through clinical development and exploring partnerships, including a recent collaboration with Halozyme, to position CB1 inhibition as a complementary mechanism in the large and heterogeneous obesity market.
View full company profile